No Data
No Data
Shanghai Xuerong Biotechnology Co.,Ltd. (SZSE:300511) Surges 36% Yet Its Low P/S Is No Reason For Excitement
Xuerong Biology: 2024 Semi-Annual Report
Xuerong Biology: 2024 Semi-Annual Report Summary
Shanghai Xuerong Biotechnology Co.,Ltd. (SZSE:300511) Stock Catapults 45% Though Its Price And Business Still Lag The Industry
Shanghai Xuerong Bio-Technology (300511.SZ): Intends to repurchase 31.03% equity of Lin Tao Xuerong held by the fund.
On August 5th, Gelunhui reported that Shanghai Xuerong Bio-technology (300511.SZ) held the 12th meeting of the fifth board of directors on August 5, 2024, and passed the Proposal on Repurchasing the Equity of Subsidiaries with 6 votes in favor, 0 votes against and 0 abstentions. According to the arrangements for equity repurchase stipulated in the capital increase and share expansion agreement, the company and Linchuan Xuerong, along with Gansu Industrial Development Investment Fund Co., Ltd. (hereinafter referred to as 'Investment Fund'), signed the 'Agreement on Repurchase and Share Transfer of Linchuan Xuerong Bio-technology Co., Ltd.'s Held by Investment Fund' on August 5th, 2024, with the company repurchasing Linchuan Xuerong held by Investment Fund.
Xuerong Biology (300511.SZ): In 2023, the production of enoki mushrooms was 366,700 tons, and the production of shimeji mushrooms was 81,700 tons
Shanghai Xuerong Bio-Technology (300511.SZ) stated on the investor communication platform that the company's main raw materials include rice bran, corn cob, bran, cottonseed hulls, beer dregs, etc. The company's suppliers are widely distributed and numerous, and there is no reliance on a single supplier. In 2023, the company's production of shiitake mushrooms was 366,700 tons, and the production of enoki mushrooms was 81,700 tons.
No Data
No Data